National Academies Press: OpenBook
« Previous: 12 Summary and Conclusions
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×

References

1. F. Fenner, D.A. Henderson, I. Arita, J. Jezek, and L.D. Ladnyi. Smallpox and Its Eradication. Geneva: World Health Organization, 1988.

2. Encyclopedia Britannica. "Smallpox" (CD-ROM). 1998.

3. A. Cann. Principles of Molecular Virology. London: Academic Press, 1997.

4. K. Alibek. Testimony before the U.S. Congress, Joint Economic Committee. "Terrorist and Intelligence Operations: Potential Impact on the U.S. Economy." May 20, 1998.

5. H.L. Ploegh. Viral strategies of immune evasion. Science 280:248–253, 1998.

6. R.F. Massung, V.N. Loparev, J.C. Knight, A.V. Totmenin, V.E. Chizhikov, J.M. Parsons, et al. Terminal refion sequence variations in variola virus DNA. Virology 221 (2):291–300, 1996.

7. B. Moss. Poxviridae: The viruses and their replication. In B.N. Fields, D.M. Knipe, and P.M. Howley, eds., Fields Virology. 3rd ed., Vol. 2. Philadelphia: Lippincott-Raven, 1996.

8. T.G. Senkevich, E.V. Koonin, J.J. Bugert, G. Darai, and B. Moss. The genome of molluscum contagiosum virus: Analysis and comparison with other poxviruses. Virology 233(1):19–421, 1997.

9. E.J.H.J. Wiertz, D. Sotorella, M. Bogyo, J. Yu, W. Mothes, T.R. Jones, et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384(6608):432–438, 1996.

10. Encyclopedia Britannica. "Viruses: The Cycle of Infection" (CD-ROM). 1998.

11. F. Fenner and R.M.L. Bullet. Mousepox. In N. Nathanson, ed., Viral Pathogenesis. Philadelphia: Lippincott Raven, 1997.

Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×

12. Encyclopedia Britannica. "Jenner, Edward" (CD-ROM). 1998.

13. United Kingdom Ministry of Health. Smallpox 1961–63. In Reports on Public Health and Medical Subjects, No. 109. London: Her Majesty's Stationary Office, 1963.

14. T. Mack. Smallpox in Europe. Journal of Infectious Disease 125(2): 161–169, 1972.

15. D.A. Henderson. Historical Background. Paper prepared for the Workshop of the IOM Committee on Assessment of Future Scientific Needs for Live Variola Virus, 20 November 1998, Washington, D.C.

16. WHO (World Health Organization). Report of the Meeting of the Ad Hoc Committee on Orthopox Virus Infections. Geneva: World Health Organization, 1994.

17. NIH (National Institutes of Health). "Guidelines for Research Involving Recombinant DNA Molecules" (Online). Available at: http://www.nih.gov/od/ orda/apndxg.htm. Accessed 15 December 1998.

18. G. Holzer and F.G. Falkner. Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. Journal of Virology 71(7):4997–5002, 1997.

19. WHO (World Health Organization). "World Health Assembly Closes in Geneva" (press release). 27 May 1996. Available at: http://www.who.int/inf-pr-1996/wha96-11.html. Accessed October 23, 1998

20. WHO (World Health Organization). Destruction of the smallpox virus. Weekly Epidemiological Report (serial online) 74(4):27–28, 29 January 1999. Available at: http://www.who.int/wer/pdf/1999/wer7404.pdf. Accessed 3 February 1999.

21. U.S. Department of Defense/Department of Health and Human Services Smallpox Research Group. Smallpox Research Plan, Memorandum of Transmittal to National Security Council (Daniel Ponneman), 30 June 1995.

22. J. Neyts and E. De Clercq. Efficacy of (S)-1-(3-hydroxy-2 phosphonyl-methoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. Journal of Medical Virology 41(3):242–246, 1993.

23. K.P. Meadows, S.K. Tyring, A.T. Pavia, and T.M. Rallis. Resolutionof recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir . Archives of Dermatology 133(8):987–990, 1997.

24. J. W. Huggins. Presentation at the Workshop of the IOM Committee on Assessment of Future Scientific Needs for Live Variola Virus, 20 November 1998, Washington, D.C.

25. P.B. Jahrling. Presentation at the Workshop of the IOM Committee on Assessment of Future Scientific Needs for Live Variola Virus, 20 November 1998, Washington, D.C.

Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×

26. J.J. Esposito. Comment at the Workshop of the IOM Committee on Assessment of Future Scientific Needs for Live Variola Virus, 20 November 1998, Washington, D.C.

27. E. De Clerc q. Antiviral drug discovery. In G.J. Galasso, R.J. Whitley, and T.C. Merigan, eds., Antiviral Agents and Human Viral Diseases. Philadelphia: Lippincott-Raven, 1997.

28. Physicians' Desk Reference. 52nd ed. Oradell, N.J.: Medical Economics Co., 1998.

29. B.N. Fields, D.M. Knipe, and P.M. Howley. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996.

30. M.S. Hirsch, B. Conway, R.T. D'Aquila, V.A. Johnson, F. Brun-Vezinet, B. Clotet, et al. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society—USA Panel. Journal of the American Medical Association 279(24):1984–1991, 1998.

31. B. Mahy and L.Collier, eds. Virology. Topley and Wilson's Microbiology and Microbial Injections. Vol. 1. London: Oxford University Press, 1998.

32. CDC (Centers for Disease Control and Prevention). Vaccinia (smallpox) vaccine recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report 40(R14): 1–10, 1991.

33. R.R. Redfield, D.C. Wright, W.D. James, T.S. Jones, C. Brown, and D.S. Burke. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. New England Journal of Medicine 316(11):673–676, 1987.

34. CDC (Centers for Disease Control and Prevention). Epidemiologicnotes and reports: Disseminated vaccinia infection in a college student in Tennessee . Morbidity and Mortality Weekly Report 31 (50):682–683,1982.

35. CDC (Centers for Disease Control and Prevention). Notice to readers: smallpox vaccine no longer available for civilians—United States. Morbidity and Mortality Weekly Report 32(29):387, 1983.

36. S.N. Shchelkunov, R.F. Massung, and J.J. Esposito. Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. Virus Research 36:107–118, 1995.

37. J.J. Esposito. Presentation at the Workshop of the IOM Committee on Assessment of Future Scientific Needs for Live Variola Virus, 20 November 1998, Washington, D.C.

38. R.F. Massung, J.C. Knight, and J.J. Esposito. Topography of variola smallpox virus inverted terminal repeats. Virology 211:350–355, 1995.

39. H. Neubauer, U. Reischl, S. Ropp, J.J. Esposito, H. Wolf, and H. Meyer. Specific detection of monkeypox virus by polymerase chain reaction. Journal of Virological Methods 74(2):201–207, 1998.

Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×

40. M.S. Ibrahim, J.J. Esposito, P.B. Jahrling, and R.S. Lofts. The potential of 5' nuclease PCR for detecting a single-base polymorphism in orthopoxvirus. Molecular Cell Probes 11(2): 143–147, 1997.

41. S.L. Ropp, Q. Jin, J.C. Knight, R.F. Massung, and J.J. Esposito. PCR strategy for identification and differentiation of smallpox and other orthopoxviruses. Journal of Clinical Microbiology 33(8):2069–2076, 1995.

42. F. Scheiflinger, F. Dorner, and F.G. Falkner. Construction of chimeric vaccinia viruses by molecular cloning and packaging. Proceedings of the National Academy of Sciences 89:9977–9981, 1992.

43. P.C. Turner and R.W. Moyer. The molecular pathogenesis of poxviruses. Current Topics in Microbiology and Immunology 163:125–151, 1990.

44. R.M. Buller and O.J. Palumbo. Poxvirus pathogenesis. Microbiological Review 55:80–122, 1991.

45. G.J. Kotwal. Microorganisms and their interaction with the immune system. Journal of Leukocyte Biology 62(4):415–429, 1997.

46. G. McFadden. DNA viruses that affect cytokine networks. In B.B. Aggarwal and R.K. Purl, eds., Human Cytokines: Their Role in Disease and Therapy. Cambridge, Mass.: Blackwell Press, 1995.

47. G. McFadden. Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses. Austin, Tex.: R.G. Landes Co., 1995.

48. G.L. Smith, J.A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcami. Vaccinia virus immune evasion. Immunological Reviews 159:137–154, 1997.

49. M.K. Spriggs. One step ahead of the game: Viral immunomodulatory molecules. Annual Review of Immunology 14:101–131, 1996.

50. R.M. Zinkernagel. Immunology taught by viruses. Science 271(5246): 173–178, 1996.

51. M. Barry and G. McFadden. Virokines and viroceptors. In D.G. Remick and J.S. Friedland, eds., Cytokines in Health and Disease. New York: Marcel Dekker, 1997.

52. B. MOSS. Replication of poxviruses. In B.N. Fields, D.M. Knipe, and P.M. Howley, eds. Fields Virology, 3rd ed. Philadelphia: Lippincott-Raven, 1996.

53. A.S. Lalani and G. McFadden. Secreted poxvirus chemokine binding proteins. Journal of Leukocyte Biology 62, 1997.

54. P.C. Turner, P.Y. Musy and R.W. Moyer. Poxvirus serpins. In O. McFadden, ed., Viroceptors, Virokines, and Related Immune Modulators Encoded by DNA Viruses. Austin, Tex.: R.G. Landes Co., 1995.

55. D.A. Lomas, D.L. Evans, C. Upton, G. McFadden, and R.W. Carrell. Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. Journal of Biological Chemistry 268(1):516–521, 1993.

Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×

56. P. Nash, A. Lucas, and G. McFadden. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. In F.C. Church, D.D. Cunningham, D. Ginsburg, M. Hoffman, S.R. Stone, and D.M. Tollefsen, eds., Chemistry and Biology of Serpins. New York: Plenum Press, 1997.

57. A. Lucas, Y. Liu, J. Macen, P. Nash, E. Dai, M. Stewart, et al. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 94(11):2890–2900, 1996.

58. G. McFadden and M. Barry. How poxviruses oppose apoptosis. Virology 8:429–442, 1998.

59. J.A. Macen, K.B. Takahashi, K.B. Moon, R. Nathaniel, P.C. Turner, and R.W. Moyer. Activation of capsizes in pig kidney cells infected with wild type and cram/SIP-2 mutants of cowpox and rabbitpox viruses. Journal of Virology 72(5):3524–3533, 1998.

60. G. McFadden, K. Graham, and M. Barry. New strategies of immune modulation by DNA viruses. Transplantation Proceedings 28(4):2085–2088, 1996.

Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
This page in the original is blank.
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
Page 87
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
Page 88
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
Page 89
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
Page 90
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
Page 91
Suggested Citation:"References." Institute of Medicine. 1999. Assessment of Future Scientific Needs for Live Variola Virus. Washington, DC: The National Academies Press. doi: 10.17226/6445.
×
Page 92
Next: Appendix A Glossary »
Assessment of Future Scientific Needs for Live Variola Virus Get This Book
×
Buy Paperback | $44.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In 1980, the World Health Organization (WHO) officially declared that smallpox had been eradicated. In 1986, WHO's international Ad Hoc Committee on Orthopox Virus Infections unanimously recommended destruction of the two remaining official stocks of variola virus, one at the Centers for Disease Control and Prevention and the other at the VECTOR laboratory in Siberia. In June 1999, WHO decided to delay the destruction of these stocks. Informing that decision was Assessment of Future Scientific Needs for Variola Virus, which examines:

  • Whether the sequenced variola genome, vaccinia, and monkey pox virus are adequate for future research or whether the live variola virus itself is needed to assist in the development of antiviral therapies.
  • What further benefits, if any, would likely be gained through the use of variola in research and development efforts related to agent detection, diagnosis, prevention, and treatment.
  • What unique potential benefits, if any, the study of variola would have in increasing our fundamental understanding of the biology, host-agent interactions, pathogenesis, and immune mechanisms of viral diseases.
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!